Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome—insights from a UK center
The study illustrates the limitations of relying solely on platelet counts to estimate bleeding risk in MPN patients. Assessment of VWF activity and careful selection of antithrombotic therapy were highlighted as important considerations.
Authors
- Zain Odho (ORCID: https://orcid.org/0000-0002-5176-4364)
- G. Simini (ORCID: https://orcid.org/0000-0002-5825-2927)
- Simone Claudiani (ORCID: https://orcid.org/0000-0003-3686-7610)
- Golzar Mobayen (ORCID: https://orcid.org/0009-0007-3847-5035)
- Andrew J. Innes (ORCID: https://orcid.org/0000-0003-0918-8882)
- Michael Laffan (ORCID: https://orcid.org/0000-0002-8268-3268)
- Deepa J. Arachchillage (ORCID: https://orcid.org/0000-0001-5993-4850)
- Nilanthi Karawitage
- Saravanan Vinayagam
Institutions
- Imperial College Healthcare NHS Trust (GB)
- University College London (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1016/j.rpth.2025.102954
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Imperial College London